• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ALLOPURINOL Drug Record

  • Summary
  • Interactions
  • Claims
  • ALLOPURINOL chembl:CHEMBL1467 Approved

    Alternate Names:

    HAMARIN 100
    ALORAL
    ZYLOPRIM
    COSURIC
    BW-56158
    ALLOPURINOL
    XANTHOMAX-100
    LOPURIN
    URICTO
    ZYLORIC-300
    LEDOPUR
    NSC-101655
    CAPLENAL
    NSC-1390
    XANTHOMAX-300
    HAMARIN 300
    ALULINE 100
    BW-56-158
    ALULINE 300
    ZYLORIC
    4-HYDROXYPYRAZOLOPYRIMIDINE
    ALLOPURINOLUM
    1H-PYRAZOLO(3,4-D)PYRIMIDIN-4-OL
    1,5-DIHYDRO-4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE
    1H,2H,4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE
    4'-HYDROXYPYRAZOLOL(3,4-D)PYRIMIDINE
    ZYLOPRIM®
    4-HYDROXYPYRAZOLYL(3,4-D)PYRIMIDINE
    4-HPP
    ALLOPURINOLUM [INN-LATIN]
    ALOPURINOL
    4-HYDROXYPYRAZOLO(3,4-D)PYRIMIDINE
    4-HYDROXY-1H-PYRAZOLO(3,4-D)PYRIMIDINE
    4-HYDROXY-3,4-PYRAZOLOPYRIMIDINE
    ALOPURINOL [INN-SPANISH]
    4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE
    1,5-DIHYDRO-4H-PYRAZOLO(3,4-D)PYRIMIDINE-4-ONE
    ALOPRIM®
    AL-100
    drugbank:00437
    rxcui:519
    chemidplus:315-30-0
    chembl:CHEMBL1467
    pubchem.compound:2094

    Drug Info:

    Year of Approval 1980
    Drug Class gout suppressants
    Drug Indications antiuricemic agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of gout
    (3 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Cheng L et al., 2018, The minor alleles HCP5 rs3099844 A and PSORS1C1 rs3131003 G are associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese: a multicentre retrospective case-control clinical study., Br J Dermatol
    Génin E et al., 2011, Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe., Orphanet J Rare Dis
    Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int
    McDonagh EM et al., 2014, PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics., Pharmacogenet Genomics
    George et al., 2009, Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress., Vasc Health Risk Manag
    Kelley et al., 1970, Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells., J. Clin. Invest.
    Carro et al., 2010, Effects of allopurinol on uric acid concentrations, xanthine oxidoreductase activity and oxidative stress in broiler chickens., Comp. Biochem. Physiol. C Toxicol. Pharmacol.
    Dincer et al., 2002, Asymptomatic hyperuricemia: to treat or not to treat., Cleve Clin J Med
    Okamoto, 2008, [Inhibitors of xanthine oxidoreductase]., Nippon Rinsho
    Higgins et al., 2009, The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease., Cardiovasc Psychiatry Neurol
    Pacher et al., 2006, Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol., Pharmacol. Rev.
    Suzuki et al., 2009, Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders?, Drugs Today
    Taha et al., 2009, Effects of allopurinol on ischemia and reperfusion in rabbit livers., Transplant. Proc.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Terkeltaub, 2010, Update on gout: new therapeutic strategies and options., Nat Rev Rheumatol
    Brackman DJ et al., 2019, Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol., Clin Pharmacol Ther
    Wright DFB et al., 2018, The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool., Br J Clin Pharmacol
    Roberts RL et al., 2017, ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout., Pharmacogenomics J
  • ALLOPURINOL   TSHZ2

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29193002


    Sources:
    PharmGKB

  • ALLOPURINOL   NTNG1

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126


    Sources:
    PharmGKB

  • ALLOPURINOL   GREM2

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126


    Sources:
    PharmGKB

  • ALLOPURINOL   TRIB2

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126


    Sources:
    PharmGKB

  • ALLOPURINOL   TBL1XR1

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126


    Sources:
    PharmGKB

  • ALLOPURINOL   PSORS1C3

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21801394


    Sources:
    PharmGKB

  • ALLOPURINOL   MYT1L

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126


    Sources:
    PharmGKB

  • ALLOPURINOL   PKD2

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126


    Sources:
    PharmGKB

  • ALLOPURINOL   CYCSP5

    Interaction Score: 3.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29193002 21801394


    Sources:
    PharmGKB

  • ALLOPURINOL   XDH

    Interaction Score: 1.83

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Xanthine dehydrogenase inhibitor
    Trial Name NU1618, tranilast + allopurinol

    PMIDs:
    27798726 24915143 19436671 5415686 19654053 12184468 18409526 20029618 16507884 19584965 19376361 11752352 20046204


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ALLOPURINOL   PSORS1C1

    Interaction Score: 1.6

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29193002 21801394


    Sources:
    PharmGKB

  • ALLOPURINOL   POU5F1

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21801394


    Sources:
    PharmGKB

  • ALLOPURINOL   NOTCH4

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29193002


    Sources:
    PharmGKB

  • ALLOPURINOL   AOX1

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A5

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A7

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A10

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A8

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A6

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A4

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A3

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A9

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   ABCG2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126 29341237 26810134


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ALLOPURINOL   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ALLOPURINOL   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ALLOPURINOL   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ALLOPURINOL   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ALLOPURINOL   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: ALLOPURINOL

    • Version: 01-August-2011

    Alternate Names:
    ALLOPURINOL Primary Drug Name

    Drug Info:
    Drug Class gout suppressants
    Year of Approval 1980

    Publications:

  • TdgClinicalTrial: ALLOPURINOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of gout
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: ALLOPURINOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1467 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: allopurinol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Génin E et al., 2011, Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe., Orphanet J Rare Dis
    Cheng L et al., 2018, The minor alleles HCP5 rs3099844 A and PSORS1C1 rs3131003 G are associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese: a multicentre retrospective case-control clinical study., Br J Dermatol
    Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int

  • TTD: Allopurinol

    • Version: 2020.06.01

    Alternate Names:
    D04KYY TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1467

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1467

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21